CA2520945C - Assessing neuronal damage from blood samples - Google Patents
Assessing neuronal damage from blood samples Download PDFInfo
- Publication number
- CA2520945C CA2520945C CA2520945A CA2520945A CA2520945C CA 2520945 C CA2520945 C CA 2520945C CA 2520945 A CA2520945 A CA 2520945A CA 2520945 A CA2520945 A CA 2520945A CA 2520945 C CA2520945 C CA 2520945C
- Authority
- CA
- Canada
- Prior art keywords
- sample
- antibody
- injury
- blood
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 title claims description 40
- 239000008280 blood Substances 0.000 title claims description 40
- 230000003961 neuronal insult Effects 0.000 title abstract description 6
- 230000006378 damage Effects 0.000 claims abstract description 69
- 208000014674 injury Diseases 0.000 claims abstract description 64
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 62
- 230000001537 neural effect Effects 0.000 claims abstract description 48
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 43
- 210000002966 serum Anatomy 0.000 claims description 20
- 210000002381 plasma Anatomy 0.000 claims description 8
- 238000003119 immunoblot Methods 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003593 chromogenic compound Substances 0.000 claims description 2
- 230000000951 immunodiffusion Effects 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 210000005044 neurofilament Anatomy 0.000 abstract description 24
- 102000008763 Neurofilament Proteins Human genes 0.000 abstract description 23
- 108010088373 Neurofilament Proteins Proteins 0.000 abstract description 23
- 239000000523 sample Substances 0.000 abstract description 21
- 239000012472 biological sample Substances 0.000 abstract description 10
- 230000015556 catabolic process Effects 0.000 abstract description 7
- 238000003556 assay Methods 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 19
- 210000002569 neuron Anatomy 0.000 description 17
- 238000001514 detection method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 13
- 238000012286 ELISA Assay Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- 108010079337 Tissue Polypeptide Antigen Proteins 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 239000003656 tris buffered saline Substances 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 6
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000020431 spinal cord injury Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 4
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 4
- 102100028465 Peripherin Human genes 0.000 description 4
- 108010003081 Peripherins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000005047 peripherin Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000005890 Spectrin Human genes 0.000 description 3
- 108010019965 Spectrin Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000003140 astrocytic effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009519 contusion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002684 laminectomy Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241001546602 Horismenus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000838698 Togo Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 1
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003914 blood derivative Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000013290 female long evans rat Methods 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108010006620 fodrin Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108010091047 neurofilament protein H Proteins 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- -1 such as the calpains Proteins 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45928603P | 2003-03-31 | 2003-03-31 | |
| US60/459,286 | 2003-03-31 | ||
| PCT/US2004/009114 WO2004091379A2 (en) | 2003-03-31 | 2004-03-26 | Assessing neuronal damage from blood samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2520945A1 CA2520945A1 (en) | 2004-10-28 |
| CA2520945C true CA2520945C (en) | 2014-03-25 |
Family
ID=33299668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2520945A Expired - Fee Related CA2520945C (en) | 2003-03-31 | 2004-03-26 | Assessing neuronal damage from blood samples |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20040241762A1 (enExample) |
| EP (1) | EP1613204B1 (enExample) |
| JP (1) | JP4557971B2 (enExample) |
| AT (1) | ATE440286T1 (enExample) |
| AU (1) | AU2004229317B2 (enExample) |
| CA (1) | CA2520945C (enExample) |
| DE (1) | DE602004022645D1 (enExample) |
| DK (1) | DK1613204T3 (enExample) |
| ES (1) | ES2332136T3 (enExample) |
| WO (1) | WO2004091379A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113798A2 (en) * | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
| US20070276275A1 (en) * | 2006-05-24 | 2007-11-29 | University Of Miami | Screening method and system to estimate the severity of injury in critically ill patients |
| JPWO2008078809A1 (ja) * | 2006-12-27 | 2010-04-30 | 独立行政法人科学技術振興機構 | 鳥類抗体を使用する免疫学的検出方法 |
| US20140038834A1 (en) * | 2010-07-07 | 2014-02-06 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | Novel biomarkers for detecting neuronal loss |
| EP3129780A4 (en) * | 2014-04-07 | 2017-12-13 | Iron Horse Diagnostics Inc. | Traumatic brain injury and neurodegenerative biomarkers, methods, and systems |
| CN112823048A (zh) * | 2018-07-27 | 2021-05-18 | 维拉维斯公司 | 消除和富集的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU86652A1 (de) * | 1986-11-10 | 1988-06-13 | Progen Biotechnik Gmbh | Verfahren zum auffinden von gewebslaesionen |
| DE68927459T2 (de) * | 1988-12-21 | 1997-04-24 | Gen Hospital Corp | Nachweis einer neurologischen Krankheit oder einer Funktionsstörung |
| US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
| GB9719879D0 (en) * | 1997-09-19 | 1997-11-19 | Neuropa Ltd | Protein |
| US6589746B1 (en) * | 1999-10-21 | 2003-07-08 | University Of Cincinnati | Method of detecting axonally-derived protein tau in patients with traumatic CNS injury |
-
2004
- 2004-03-26 ES ES04758954T patent/ES2332136T3/es not_active Expired - Lifetime
- 2004-03-26 JP JP2006509274A patent/JP4557971B2/ja not_active Expired - Fee Related
- 2004-03-26 AT AT04758954T patent/ATE440286T1/de not_active IP Right Cessation
- 2004-03-26 CA CA2520945A patent/CA2520945C/en not_active Expired - Fee Related
- 2004-03-26 EP EP04758954A patent/EP1613204B1/en not_active Expired - Lifetime
- 2004-03-26 DK DK04758954T patent/DK1613204T3/da active
- 2004-03-26 DE DE602004022645T patent/DE602004022645D1/de not_active Expired - Lifetime
- 2004-03-26 AU AU2004229317A patent/AU2004229317B2/en not_active Ceased
- 2004-03-26 US US10/810,388 patent/US20040241762A1/en not_active Abandoned
- 2004-03-26 WO PCT/US2004/009114 patent/WO2004091379A2/en not_active Ceased
-
2010
- 2010-03-17 US US12/726,064 patent/US20100184105A1/en not_active Abandoned
-
2014
- 2014-11-21 US US14/550,240 patent/US20160349272A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4557971B2 (ja) | 2010-10-06 |
| EP1613204A2 (en) | 2006-01-11 |
| EP1613204B1 (en) | 2009-08-19 |
| WO2004091379A2 (en) | 2004-10-28 |
| AU2004229317B2 (en) | 2012-01-12 |
| US20160349272A1 (en) | 2016-12-01 |
| ATE440286T1 (de) | 2009-09-15 |
| DE602004022645D1 (de) | 2009-10-01 |
| WO2004091379A3 (en) | 2005-12-22 |
| DK1613204T3 (da) | 2009-12-07 |
| HK1085538A1 (en) | 2006-08-25 |
| JP2006522336A (ja) | 2006-09-28 |
| US20040241762A1 (en) | 2004-12-02 |
| AU2004229317A1 (en) | 2004-10-28 |
| EP1613204A4 (en) | 2007-04-04 |
| US20100184105A1 (en) | 2010-07-22 |
| CA2520945A1 (en) | 2004-10-28 |
| ES2332136T3 (es) | 2010-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2607285C (en) | Diagnosis of liver pathology through assessment of protein glycosylation | |
| JP5963900B2 (ja) | オートタキシン測定による悪性リンパ腫の検査方法および検査薬 | |
| US20160349272A1 (en) | Assessing neuronal damage from blood samples | |
| US20050176078A1 (en) | Detection and/or monitoring of synuclein-related diseases | |
| JP2008175814A (ja) | 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット | |
| JPH06502912A (ja) | アナライト変異体分析 | |
| JP5322556B2 (ja) | 新規非アルコール性脂肪性肝疾患バイオマーカーおよび該バイオマーカーを用いた非アルコール性脂肪性肝疾患の検出方法 | |
| JP7449530B2 (ja) | 腎癌の検出方法及び検査薬 | |
| CN114573692A (zh) | 用于检测嗜铬粒蛋白a的免疫测定与抗体 | |
| JP2000515854A (ja) | 脳タンパク質ｓ―１００の存在の測定方法 | |
| JP7709703B2 (ja) | 膵臓がんの検出方法及び検出試薬 | |
| AU2012202051A1 (en) | Assessing neuronal damage from blood samples | |
| HK1085538B (en) | Assessing neuronal damage from blood samples | |
| JPH07309895A (ja) | 新規タンパク質、その検出方法及び診断薬 | |
| WO2003104812A2 (en) | ASSAY FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE RATIO OF hAβ42:hAβ40 | |
| WO2025182761A1 (ja) | Ｇｆａｐの検出方法、アルツハイマー病の診断を補助する方法、及びそれらに用いるキット | |
| JP6817666B2 (ja) | 精神疾患発症危険状態の診断用バイオマーカー | |
| AU2012247075B2 (en) | Diagnosis of liver pathology through assessment of protein glycosylation | |
| JP2003277398A (ja) | トランスフェリンを含む免疫複合体に対する抗体、抗体の製造方法、ハイブリドーマ及び免疫測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160329 |